Clinical trials: Familial Pulmonary Fibrosis
Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe.
- Conditions
- Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
- Trial name
- NCT07201922
- Testing
- Nerandomilast
- Where
- 55 sites in United States, Argentina and 11 more
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Telomere Biology Disorders, Dyskeratosis Congenita
Nucleoside Therapy in Patients With Telomere Biology Disorders
The goal of this clinical trial is to learn if a combination therapy of deoxycytidine (dC) plus deoxythymidine (dT) is safe in patients with telomere biology disorders.
- Conditions
- Telomere Biology Disorders, Dyskeratosis Congenita, Revesz Syndrome, Hoyeraal Hreidarsson Syndrome
- Trial name
- NCT06817590
- Testing
- deoxycytidine, deoxythymidine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Suneet Agarwal
Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder), Idiopathic Pulmonary Fibrosis (IPF)
Hereditary Influences on Pulmonary Fibrosis Trajectories
The SHIFT (Hereditary Influences on Pulmonary Fibrosis Trajectories) study is a prospective, multicenter, observational cohort study designed to investigate familial pulmonary fibrosis (FPF) within the Italian population.
- Conditions
- Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder), Idiopathic Pulmonary Fibrosis (IPF), Telomere Disease, Progressive Pulmonary Fibrosis
- Trial name
- SHIFT (NCT07580053)
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Istituto Clinico Humanitas
Interstitial Lung Disease, Pulmonary Fibrosis
P4O2 ILD Extension
The goal of this observational study is to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (PPF) in participants with interstitial lung diseases (ILDs).
- Conditions
- Interstitial Lung Disease, Pulmonary Fibrosis, Interstitial Lung Fibrosis, IPF
- Trial name
- P4O2-ILD (NCT06644144)
- Testing
- No Interventions
- Where
- Netherlands
- Volunteers
- 450 people
- Sponsor
- Amsterdam UMC, location VUmc
Familial Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
Mechanisms of Familial Pulmonary Fibrosis
This a prospective, longitudinal study of first-degree family members of patients diagnosed with familial interstitial pneumonia (FIP).
- Conditions
- Familial Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Familial Interstitial Pneumonia
- Trial name
- NCT03437486
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Vanderbilt University Medical Center
Familial Pulmonary Fibrosis
GEN-FPF: Genetic Exploration of Familial Pulmonary Fibrosis
Pulmonary fibrosis (PF) is a progressive lung disease marked by tissue scarring and impaired breathing. Familial pulmonary fibrosis (FPF) makes up 10-20% of PF cases and shares features with idiopathic PF (IPF), but the genetic…
- Trial name
- GEN-FPF (NCT07251725)
- Where
- Italy
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia
- Trial name
- NCT02036970
- Testing
- Bardoxolone methyl
- Where
- 32 sites in United States, Germany
- Volunteers
- 166 people
- Sponsor
- Biogen
Connective Tissue Diseases, Interstitial Lung Disease
Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland
This study aims to improve the understanding of how genes and the environment can influence and cause pulmonary fibrosis. By identifying the presence of genes and other factors that can put people at risk of developing pulmonary…
- Conditions
- Connective Tissue Diseases, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Familial Idiopathic Pulmonary Fibrosis
- Trial name
- PRECISE-PF (NCT06702228)
- Testing
- Six minute walk test (6MWT), Computer-tomography of the thorax (CT Thorax), Quality of life questionnaires.
- Where
- Ireland
- Volunteers
- 300 people
- Sponsor
- Royal College of Surgeons, Ireland
Familial Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
Clinical Genetics and Screening for Idiopathic Pulmonary Fibrosis
Background: Idiopathic pulmonary fibrosis (IPF) is the most common and severe form of interstitial lung disease. Between 2% and 20% of patients with IPF have a family history of the disease, which is considered the strongest risk…
- Trial name
- GENESI (NCT06521125)
- Testing
- High resolution Computed Tomography (HRCT) scans of the Chest, Pulmonary Function Testing (PFTs), Digital lung sounds auscultation
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease
Interstitial lung disease (ILD) is the result of over 200 etiological pathways arising from several different insults to the lung parenchyma: inhaled substances, drug side effects, connective tissue disease, infection, and…
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Interstitial Pneumonitis, Desquamative Interstitial Pneumonia
- Trial name
- NCT02019641
- Testing
- Aerobic Exercise Training (AET), Education
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Pulmonary Fibrosis Idiopathic Familial
Optimising Screening for Early Disease Detection in Familial Pulmonary Fibrosis
In this study the prognostic value of the current screening parameters for familial pulmonary fibrosis (FPF) will be investigated by looking at the screenings of 200 first-degree relatives of patients with FPF.
- Trial name
- FLORIS (NCT05367349)
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- St. Antonius Hospital
Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis.
- Conditions
- Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, Familial Interstitial Pneumonia
- Trial name
- GWAS (NCT01088217)
- Where
- 4 sites in United States, Iceland
- Volunteers
- 8,000 people
- Sponsor
- National Jewish Health
Interstitial Pulmonary Fibrosis ARDS, COPD (Chronic Obstructive Pulmonary Disease)
The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients
ECMO(Extracorporeal membrane oxygenation) is being essential for cardiopulmonary failure patients. There are two types of ECMO, which is veno-veno (V-V) that can be used in respiratory failure patients and veno-arterial (V-A)…
- Conditions
- Interstitial Pulmonary Fibrosis ARDS, COPD (Chronic Obstructive Pulmonary Disease), Bronchiectasis, Lymphangioleiomyomatosis
- Trial name
- NCT02859194
- Testing
- Veno-veno-arterial ECMO
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Yonsei University